---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: [Remarkably Reduced Tumor Marker SCC Levels by Combined Chemotherapy of Paclitaxel and S-1 in Two Cases of Advanced Cervical Cancer.]
To: mesothelioma77@gmail.com
[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 335-337
Takagi K, Kougo H, Aoyagi Y, Yonehara T, Minobe S, Azuma M, Yamaguchi T
Case 1: A-35-year-old woman was diagnosed as cervical cancer Stage IIIb. When admitted to the hospital, her tumor marker SCC level was 50 ng/mL. Concurrent chemoradiation therapy was started on November, 2005. The SCC level was reduced by 0.9 ng/mL in February, 2006. In April, tumor recurrence was found by PET, and chemotherapy was restarted, but the SCC level was increased. In September, paclitaxel/S-1therapy was performed, and the tumor mark- ers were again reduced remarkably (SCC 9.8--> 1.3 ng/mL). Case 2: A-78-year-old woman was diagnosed as cervical cancer Stage IIIb. In August, 2004, concurrent chemoradiation therapy was started, and tumor markers were reduced (SCC 25.4--> 1.8 ng/mL). However, tumor markers were increased soon after the therapy. Chemotherapy was started, but it could not be maintained because of the side effects. In April, 2006, paclitaxel/S-1therapy was performed, and the tumor markers were reduced remarkably (SCC 120--> 10 ng/mL). However, that therapy could also not be maintained because of the side effect. In July, she died of the cancer.
___
Source: http://www.hubmed.org/display.cgi?uids=18281778
--
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Feb 20, 2008 4:02 AM
Subject: [Remarkably Reduced Tumor Marker SCC Levels by Combined Chemotherapy of Paclitaxel and S-1 in Two Cases of Advanced Cervical Cancer.]
To: mesothelioma77@gmail.com
[1]Gan To Kagaku Ryoho. 2008 Feb; 35(2): 335-337
Takagi K, Kougo H, Aoyagi Y, Yonehara T, Minobe S, Azuma M, Yamaguchi T
Case 1: A-35-year-old woman was diagnosed as cervical cancer Stage IIIb. When admitted to the hospital, her tumor marker SCC level was 50 ng/mL. Concurrent chemoradiation therapy was started on November, 2005. The SCC level was reduced by 0.9 ng/mL in February, 2006. In April, tumor recurrence was found by PET, and chemotherapy was restarted, but the SCC level was increased. In September, paclitaxel/S-1therapy was performed, and the tumor mark- ers were again reduced remarkably (SCC 9.8--> 1.3 ng/mL). Case 2: A-78-year-old woman was diagnosed as cervical cancer Stage IIIb. In August, 2004, concurrent chemoradiation therapy was started, and tumor markers were reduced (SCC 25.4--> 1.8 ng/mL). However, tumor markers were increased soon after the therapy. Chemotherapy was started, but it could not be maintained because of the side effects. In April, 2006, paclitaxel/S-1therapy was performed, and the tumor markers were reduced remarkably (SCC 120--> 10 ng/mL). However, that therapy could also not be maintained because of the side effect. In July, she died of the cancer.
___
Source: http://www.hubmed.org/display.cgi?uids=18281778
--